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Abstract 
Background: l‑Arginine is a semi‑essential aminoacid with important role in regulation of physiological processes 
in humans. It serves as precursor for the synthesis of proteins and is also substrate for different enzymes such as nitric 
oxide synthase. This amino‑acid act as free radical scavenger, inhibits the activity of pro‑oxidant enzymes and thus 
acts as an antioxidant and has also bactericidal effect against a broad spectrum of bacteria.
Results: New thiazolidine‑4‑one derivatives of nitro‑l‑arginine methyl ester (NO2‑Arg‑OMe) have been synthe‑
sized and biologically evaluated in terms of antioxidant and antibacterial/antifungal activity. The structures of the 
synthesized compounds were confirmed by 1H, 13C NMR, Mass and IR spectral data. The antioxidant potential was 
investigated using in vitro methods based on ferric/phosphomolybdenum reducing antioxidant power and DPPH/
ABTS radical scavenging assay. The antibacterial effect was investigated against Gram positive (Staphylococcus aureus 
ATCC 25923, Sarcina lutea ATCC 9341) and Gram negative (Escherichia coli ATCC 25922, Pseudomonas aeruginosa ATCC 
27853) bacterial strains. The antifungal activity was also investigated against Candida spp. (Candida albicans ATCC 
10231, Candida glabrata ATCC MYA 2950, Candida parapsilosis ATCC 22019).
Conclusions: Synthesized compounds showed a good antioxidant activity in comparison with the NO2‑Arg‑OMe. 
The antimicrobial results support the selectivity of tested compounds especially on P. aeruginosa as bacterial strain 
and C. parapsilosis as fungal strain. The most proper compounds were 6g (R = 3‑OCH3) and 6h (R = 2‑OCH3) which 
showed a high free radical (DPPH, ABTS) scavenging ability and 6j (R = 2‑NO2) that was the most active on both bac‑
terial and fungal strains and also it showed the highest ABTS radical scavenging ability.
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Background
l-Arginine is an amino acid with the highest nitrogen 
content known for its important role in regulation of 
physiological processes in humans [1]. This amino acid is 
considered a semi-essential amino acid because normal 
cells can not only synthesize arginine de novo through 
the ornithine cycle but also uptake extracellular arginine 
[2]. It serves as a precursor for the synthesis of proteins 
and it is also substrate for different enzymes. For exam-
ple nitric oxide synthase (NOS) converts arginine to 
nitric oxide (NO) and citrulline. Three isoforms of NOS 
have been described: endothelial NOS (eNOS), neuronal 
NOS (nNOS), that are constitutive isoforms (cNOS) and 
inducible NOS (iNOS) [3]. NO, is an important signal 
molecule, involved in immune responses, angiogenesis, 
epithelialization and formation of granulation tissue, 
vasodilatation of smooth muscle and inhibition of plate-
lets activation/aggregation [4, 5]. The cNOS produce NO 
in picomolar amounts for short time, being responsible 
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for regulation of arterial blood pressure, while iNOS 
produces large amounts of NO through cell activation 
under inflammatory conditions, appearing to be involved 
in pathophysiological phenomena [3]. Nitro-l-arginine 
methyl ester (NO2-Arg-OMe, L-NAME) is known as 
selective inhibitor of inducible NOS, which showed 
antinociceptive effects in mice and reversed thermal 
hyperalgesia in rats with carrageenan arthritis [6]. It was 
also reported that L-NAME attenuates the withdrawal 
from cocaine [7] and prevents the behaviour effects 
indused by phencyclidin, a dissociative drug [8].
l-Arginine is reported also to act as free radical scaven-
ger, inhibits the activity of pro-oxidant enzymes and thus 
acts as an antioxidant [9, 10]. This endogenous molecule 
has also bactericidal effect against a broad spectrum of 
bacteria, by nitrosation of cysteine and tyrosine residues, 
which lead to dysfunction of bacterial proteins. This 
effect could be useful in different conditions as wounds 
when infection could delay the healing process. The two 
most common bacteria in wounds are Pseudomonas aer‑
uginosa and Staphylococcus aureus [11]. In addition, to its 
role as precursor of NO, l-arginine can be metabolized 
by arginase to ornithine and urea. Ornithine is an essen-
tial precursor for collagen and polyamines synthesis, 
both required for wound healing processes [12]. Based on 
all these aspects there has been reported that l-arginine 
has important roles in Alzheimer disease [13], inflamma-
tory process [14], healing and tissue regeneration [14–16] 
and also it showed anti-atherosclerotic activity [17, 18].
On other hand the heterocyclic compounds are an inte-
gral part in organic chemistry field and constitute a mod-
ern research field that is being currently pursued by many 
research teams [19]. Diversity in the biological response of 
1,3-thiazolidine-4-one derivatives had attracted the atten-
tion of many researchers for a thorough exploration of their 
biological potential. These compounds have been reported 
for their antioxidant [20–22], anti-inflammatory [23], anti-
bacterial/antifungal [24–26], antitumor [27], antidiabetic 
[28], antihyperlipidemic [29] and antiarthritic [30] effects.
In order to improve the biological effects of l-argi-
nine and, new 1,3-thiazolidine-4-one derivatives have 
been synthesized. The spectral data (FT-IR, 1H-NMR, 
13C-NMR, MS) of each compound were recorded and the 
compounds were screened for their in  vitro antioxidant 
potential and antibacterial/antifungal activity.
Results and discussion
Chemistry
The synthesis of thiazolidine-4-one compounds derived 
from L-NO2-Arg-OMe was performed in two steps and is 
summarized in Scheme 1 and Table 1. The first step con-
sisted in formation of the 1,3-thiazolidin-4-one cycle via a 
one-pot condensation/cyclization reaction which implies 
the using of ethyl 3-aminopropionate hydrochloride 1, 
different substituted aromatic aldehydes 2a–j and thiogly-
colic acid 3 using a similar approach described in our pre-
vious work [27]. The product of this reaction was treated 
with KOH to give compounds 4 in satisfactory to very 
good overall yields. In the second and last step, the for-
mation of amide bond between acid derivatives 4 and Nω-
nitro-l-arginine methyl ester hydrochloride 5 was carried 
out using classical conditions in presence of 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) 
and 1-hydroxybenzotriazole (HOBt) to lead to new thia-
zolidine-4-one derivatives with arginine moiety 6a–j.
The structure of the compounds was assigned on the 
basis of spectral data (IR, 1H-NMR, 13C-NMR, MS) 
which are provided in the Experimental Section. The 
spectral data for compounds 4a–j were presented in our 
previous paper [31].
The analysis of IR spectral data obtained for com-
pounds 6a–j showed that the NH group corresponding 
to the amide bond formed was identified between 3305 
and 3294  cm−1 in the form of a medium or low inten-
sity bands. The specific anti-symmetric valence vibration 
of CH2 group has been reported in the range of 2940–
2825  cm−1 and overlaps with specific absorption band 
of CH group, which is identified in the same range. The 
C=O group was identified as three absorption bands: the 
absorption band in the 1760–1670 cm−1 corresponds to 
ester group (COOCH3), in the area of 1686–1647 cm−1 
was identified the absorption band corresponding 
to C=O from amide bond and the group C=O from 





























Scheme 1 Synthesis of compounds 6a–j. Reagents and conditions: a DIPEA, toluene, reflux 24–30 h; b KOH 1 M, EtOH/THF (1/1), r.t. 8–12 h then 
HCl 1 M; c Nω‑nitro‑l‑arginine methyl ester hydrochloride (5), HOBt, EDC, DCM, r.t. 10–15 h
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1647–1610  cm−1. The vibration of C–S bond, specific 
for thiazolidine-4-one, was identified between 694 and 
668 cm−1.
The formation of 6a–j has also been proved by the 
NMR data. The thiazolidine-4-one structure was proved 
by characteristic proton signals. The proton of S–CH–N 
group appears as doublet in the range of 5.72–6.08 while 
the two protons from thio-methylene group (S–CH2) 
were recorded dispersed; the first resonates between 
4.41 and 4.72  ppm, and the second between 3.80 and 
4.07 ppm. The amide bond (–NH–CO) was proved by the 
characteristic proton signal which resonates as singlet in 
the range 8.48–8.68 ppm.
In the 13C-NMR spectra the carbons of thiazolidine-
4-one system appear between 64.36 and 62.65  ppm for 
S–CH–N and between 34.53 and 33.10 ppm for –CH2–S. 
The signals for the three CO groups (COthiazolidine, COam-
ide, COester) appear in the range of 173.24–160.39  ppm, 
which confirm the success of peptide coupling reaction.
The proton and carbon signals for other characteristics 
groups were observed according to the expected chemi-
cal shift and integral values. The NMR spectral data 
coupled with mass spectra strong support the proposed 
structures of each synthesized compounds.
Biological evaluation
Antioxidant activity
The antioxidant activity was evaluated using 
in  vitro tests: DPPH and ABTS radical scavenging, 
phosphomolydenum reducing antioxidant power and 
ferric reducing antioxidant power assays. For each com-
pound it was calculated effective concentration 50 (EC50) 
by linear regression. The results were expressed as EC50 
value which represents the concentration where half of 
the substrate is being reduced by the tested compounds.
The DPPH radical scavenging assay
The purple free radical DPPH (2,2-diphenyl-1-(2,4,6-
trinitrophenyl)hydrazyl) is a stable compound that can 
be scavenged through antioxidants by reduction to 
2,2-diphenyl-1-(2,4,6-trinitrophenyl)hydrazine), a color-
less or yellow product visible at 517  nm [32]. The scav-
enging activities (%) of thiazolidine-4-one derivatives of 
nitro-l-arginine methyl ester 6a–j at different concentra-
tions (0.33, 0.66, 0.99 and 1.32 mg/mL) are presented in 
Fig. 1. The high values of the scavenging activity indicate 
a good antiradical effect. The results expressed as EC50 
values (mg/mL) are shown in Table 2. Low values of EC50 
demonstrate a higher scavenging ability.
It was observed that 1,3-thiazolidine-4-one deriva-
tives of methyl ester of nitro-l-arginine (NO2-Arg-OMe) 
showed an improved scavenging ability compared to par-
ent molecule (NO2-Arg-OMe) and l-arginine, except-
ing nitro substituted derivatives 6i and 6j, which showed 
comparable antiradical activity. It is also noted that the 
antiradical activity increases with the concentration, the 
highest inhibition being recorded at the concentration 
of 1.32 mg/mL. At this concentration the inhibition rate 
ranged from 22.62 % for 6d (R = 4-F) up to 42.61 % for 
6h (R = 2-OCH3) and 47.63 % for 6a (R = H).
The scavenging ability depends on the substitu-
ent of phenyl ring of thiazolidine-4-one moiety. The 
most active compound was unsubstituted derivative 6a 
(EC50 = 1.7294 ± 0.048), which is 1.6 times more active 
than NO2-Arg-OMe (EC50  =  2.7163  ±  0.019). A good 
influence was showed also by the methoxy substitution in 
ortho and meta position, the corresponding compounds 
6h (2-OCH3, EC50 =  1.8068 ±  0.028) and 6g (3-OCH3, 
EC50 = 1.8868 ± 0.013) being 1.5 times more active than 
NO2-Arg-OMe. All tested compounds were less active 
than vitamin E used as a positive control.
The ABTS radical scavenging assay
The radical of 2,2′-azinobis-(3-ethylbenzothiazoline-
6-sulfonic acid) (ABTS·+) generated by oxidation of 
ABTS with potassium persulfate is reduced in the pres-
ence of hydrogen-donating compounds. The influence of 
concentration of the antioxidant and duration of reaction 
on the radical cation absorption inhibition are taken into 
account for antioxidant activity evaluation [33]. The anti-
oxidants produce a discoloration with a decrease in the 
absorbance measured at 734 nm [34].
Table 1 Synthesis of derivatives 4 and 6
a Yields are indicated in isolated compounds
Entry Comp. R 4, Yielda (%) 6, Yielda (%)
1 a H 73 93
2 b 4‑CH3 55 91
3 c 4‑Cl 59 89
4 d 4‑F 67 75
5 e 4‑Br 78 87
6 f 4‑OCH3 55 86
7 g 3‑OCH3 57 78
8 h 2‑OCH3 64 76
9 i 3‑NO2 63 50
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The ABTS radical scavenging ability (%) of 6a–j at dif-
ferent concentrations (0.1, 0.15, 0.25, 0.5  mg/mL) are 
presented in Fig. 2. The high values of scavenging activity 
indicate a good antiradical effect. The results expressed 
as EC50 values (mg/mL) are presented in Table  3. Low 
values of EC50 indicate a higher effectiveness in ABTS 
scavenging ability.
The data showed that ABTS·+ is inhibited in a higher 
rate than DPPH radical, all derivatives being more active 
than parent compound. This means that the chemi-
cal modulation made on the NO2-Arg-OMe scaffold 
improves the radical scavenging activity. The radical 
scavenging ability increases with the concentration, the 
highest inhibition being recorded at the concentration of 
0.5  mg/mL (Fig.  2). At this concentration the inhibition 
rate ranged from 48.15 % for 6e (R = 4-Br) up to 89.26 % 
for 6h (R = 3-NO2) and 91.55 % for 6j (R = 2-NO2), the 
inhibition percentage being approximately 2 times higher 
than the DPPH inhibition percentage.
The activity is depending on the substitution of 
phenyl ring of thiazolidine-4-one scaffold (Table  3). 
The most active compounds were 6j, 6g and 6h 
that have nitro in ortho position and methoxy in 
ortho and para position respectively. These com-
pounds are 35 times (6j, EC50  =  0.0525  ±  0.015), 22 
times (6g, EC50  =  0.0827  ±  0.017) and 20 times (6h, 
EC50  =  0.0918  ±  0.032) more active than NO2-Arg-
OMe (EC50 = 1.8487 ± 0.026). A very good activity was 
showed also by the compounds 6c and 6d that have 
chloro and fluoro in para postion of phenyl ring. They are 
10 times (6c, EC50 = 0.1885 ± 0.014) and 11 times (6d, 
EC50  =  0.1720  ±  0.018) respectively more active than 
NO2-Arg-OMe. It is also noted that all tested compounds 
are more active than l-arginine but less active than vita-
min E used as a positive control.
Phosphomolydenum reducing antioxidant power (PRAP) 
assay
The total antioxidant activity was determined by the forma-
tion of phosphomolybdenum blue complex by the reduc-
tion of Mo6+ to Mo5+ under the action of electron donating 
compounds. The maximum absorption of the complex was 
recorded at 695 nm and the reducing antioxidant effective-
ness is correlated with high absorbance values [35]. The 
graphical representation of the absorbance values at dif-
ferent concentrations (0.18, 0.36, 0.54 and 0.72 mg/mL) is 
shown in Fig.  3. As we expected, the absorbance of 6a–j 
increases with the concentration, the highest absorbance/
activity being recorded at the concentration of 0.72 mg/mL.
The data support the positive influence of thiazoli-
dine-4-one moiety for increase the antioxidant effect 
Fig. 1 The DPPH radical scavenging ability (%) of derivatives 6a–j
Table 2 The DPPH scavenging ability (EC50 mg/mL) 
of derivatives 6a–j
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
6a 1.7294 ± 0.048 6g 1.8869 ± 0.013
6b 2.5980 ± 0.013 6h 1.8068 ± 0.028
6c 2.5354 ± 0.021 6i 2.7992 ± 0.012
6d 2.6176 ± 0.012 6j 2.8034 ± 0.014
6e 2.2430 ± 0.032 NO2-Arg-OMe 2.7163 ± 0.019
6f 2.4751 ± 0.015 L-Arg 2.8157 ± 0.017
Vitamin E 0.0018 ± 0.008
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of NO2-Arg-OMe, the corresponding compound 6a 
(EC50  =  1.6235  ±  0.015) being 1.6 times more active 
than NO2-Arg-OMe (EC50 =  2.6169 ±  0.032) (Table 4). 
Regarding the influence of radicals which substitute the 
phenyl ring from thiazolidine-4-one it was observed that 
the most favorable influence was exerted by the substi-
tution in para with Br, the corresponding compound 6e, 
(EC50 = 0.6405 ± 0.012) being 4 times more active than 
the NO2-Arg-OMe. Although the activity of the all tested 
compounds is more intense than l-arginine, they are less 
active than vitamin E used as a positive control.
Ferric reducing antioxidant power (FRAP) assay
The ferric reducing antioxidant power assay is a sensitive 
method based on the reduction of ferricyanide to fer-
rocyanide in the presence of antioxidants with electron-
donating abilities. Ferrocyanide is quantified as Perl’s 
Prussian Blue, complex which has a maximum absorp-
tion band at 700 nm [36]. The absorbance values of our 
compounds at different concentrations (0.56, 1.13, 2.27, 
4.54 mg/mL) are shown in Fig. 4 and the EC50 values are 
presented in Table 5.
The derivatization of NO2-Arg-OMe through an intro-
duction of thiazolidine-4-one moiety via amide chain 
has a great influence on antioxidant potential, all the 
tested compounds being more active than parent mol-
ecule (NO2-Arg-OMe) and l-arginine. The most active 
compounds were 6e (EC50  =  2.5781  ±  0.012) and 6c 
(EC50 = 3.2742 ± 0.019) which contain bromo and chloro 
in para position of phenyl ring. These compounds were 
4.5 times and 3.4 times respectively more active than 
NO2-Arg-OMe (EC50 = 11.0778 ± 0.016). A good influ-
ence was produced also by substitution in meta position 
with methoxy and nitro, the corresponding compounds 
being 2.5 times (6i, EC50 = 4.5202 ± 0.014) and 2.4 times 
(6g, EC50 = 4.6474 ± 0.018) more active than NO2-Arg-
OMe. All tested compounds were less active than vitamin 
E used as a positive control.
Antibacterial/antifungal assays
The antibacterial and antifungal activity of our deriva-
tives was evaluated using the agar disc diffusion method 
and broth micro-dilution method.
The agar disc diffusion method
The data presented in Table  6 show that tested com-
pounds are active on both bacterial and fungal strains, 
their effect being more intense or comparable with par-
ent molecule (NO2-Arg-OMe). The main characteristic 
of the tested compounds is their activity on P. aeruginosa 
ATCC 27853, a Gram-negative bacterial strain frequently 
Fig. 2 The ABTS radical scavenging ability (%) of derivatives 6a–j
Table 3 The ABTS scavenging ability (EC50 mg/mL) 
of derivatives 6a–j
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
6a 0.4699 ± 0.013 6g 0.0827 ± 0.017
6b 0.4967 ± 0.015 6h 0.0918 ± 0.032
6c 0.1885 ± 0.014 6i 0.9434 ± 0.018
6d 0.1720 ± 0.018 6j 0.0525 ± 0.015
6e 0.5954 ± 0.029 NO2-Arg-OMe 1.8487 ± 0.026
6f 0.4182 ± 0.012 L-Arg 2.0574 ± 0.011
Vitamin E 0.0075 ± 0.008
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found in wounds. This effect is important because Gram-
negative bacteria are more resistant than Gram-positive 
ones to the treatment due to lipopolysaccharide-rich 
outer membrane which significantly reduces the intracel-
lular penetration of antibiotics [36, 37]. It is noted that in 
similar experimental conditions, ampicillin and chloram-
phenicol, used as standard drugs, were inactive on P. aer‑
uginosa ATCC 27853, the data being in agreement with 
other experimental studies [38, 39]. The most proper 
compound seems to be 6j which has nitro in ortho posi-
tion of phenyl ring. This compound was the most active 
against S. aureus, Sarcina lutea and P. aeruginosa strains 
in comparation with NO2-Arg-OMe (5).
Regarding the antifungal activity the data support the 
positive influence of nitro substitution of phenyl ring, 
the corresponding compounds being more active than 
NO2-Arg-OMe, especially on Candida albicans (6i, 
R =  3-NO2, 6j, R =  2-NO2) and Candida glabrata (6i, 
R = 3-NO2). On C. glabrata a good activity was showed 
Fig. 3 The absorbance of derivatives 6a–j in reference with NO2‑Arg‑OMe
Table 4 The phosphomolydenum reducing antioxidant 
power (EC50 mg/mL) of 6a–j derivatives
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
6a 1.6235 ± 0.015 6g 2.7332 ± 0.037
6b 2.0679 ± 0.018 6h 3.5186 ± 0.018
6c 2.0734 ± 0.022 6i 2.1837 ± 0.024
6d 2.1706 ± 0.014 6j 2.4610 ± 0.019
6e 0.6405 ± 0.012 NO2-Arg-OMe 2.6169 ± 0.032
6f 2.3827 ± 0.013 L-Arg 2.7534 ± 0.006
Vitamin E 0.0385 ± 0.001
Fig. 4 The absorbance of derivatives 6a–j in reference with NO2‑Arg‑OMe
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also by 6d (R = 4-F). Referring to Candida parapsilosis 
strain it is noted that all tested compounds were more 
active than parent compound (NO2-Arg-OMe, 5) and 
nystatin.
The broth micro‑dilution method
After the antimicrobial activity was proved, the next 
step was to establish the minimal inhibitory concentra-
tion (MIC) and the minimal bactericidal/fungicidal con-
centration (MBC/MFC) using the broth micro-dilution 
method.
The antibacterial activity of 6j is supported by the MIC 
and MBC values (Table 7); this compound having smaller 
values than NO2-Arg-OMe for S. aureus and Escherichia 
coli. A good activity against these bacterial strains was 
also showed by the 6c, which contains chloro in para 
position of phenyl ring of thiazolidine-4-one moiety. 
The data support also the antibacterial effect of 6i and 6f 
against P. aeruginosa, their MIC and MBC values being 
smaller than NO2-Arg-OMe.
Although the results obtained using agar disc diffu-
sion method support that some of tested compounds are 
more active than positive control (ampicillin and chlo-
ramphenicol), this observation has not been proved by 
the MIC and MBC values. All tested compounds were 
less active ampicillin and chloramphenicol on tested bac-
terial strains, except P. aeruginosa ATCC 27853.
The results obtained for antifungal activity (Table  8) 
support the selectivity of the almost tested compounds, 
included the parent compound (NO2-Arg-OMe), on 
C. parapsilosis strain. For this strain the MIC values of 
almost tested compounds were comparable with nystatin 
while the MFC values were even lower than it. The data 




All chemicals used for the synthesis of the desired com-
pounds were obtained from Sigma Aldrich Company and 
Fluka Company and were used as received without addi-
tional purification. The melting points were measured 
Table 5 The ferric reducing antioxidant power (EC50, mg/
mL) of 6a–j
Data are mean ± SD (n = 3, p < 0.05)
Compound EC50 (mg/mL) Compound EC50 (mg/mL)
6a 7.1876 ± 0.038 6g 4.6474 ± 0.018
6b 9.0695 ± 0.015 6h 7.9317 ± 0.023
6c 3.2742 ± 0.019 6i 4.5202 ± 0.014
6d 8.9671 ± 0.023 6j 7.3504 ± 0.011
6e 2.5781 ± 0.012 NO2-Arg-OMe 11.0778 ± 0.016
6f 6.1302 ± 0.032 L-Arg 10.9321 ± 0.015
Vitamin E 0.0109 ± 0.003
Table 6 Antibacterial/antifungal inhibition area (mm) of 6a–j derivatives
SA = Staphylococcus aureus ATCC 25923; SL = Sarcina lutea ATCC 9341; EC = Escherichia coli ATCC 25922; PA = Pseudomonas aeruginosa ATCC 27853; CA = Candida 
albicans ATCC 10231; CG = Candida glabrata ATCC MYA 2950; CP = Candida parapsilosis ATCC 22019; 5 = NO2-Arg-OMe; A = ampicillin; C = chloramphenicol; 
N = nystatin. 5 = L-NO2-Arg-OMe
a Mean values (n = 3) ± standard deviation
Sample Diameter of inhibition areaa (mm)
Bacterial strains Yeasts strains
SA SL EC PA CA CG CP
6a 15.2 ± 0.12 19.3 ± 0.15 10.1 ± 0.06 13.1 ± 0.24 11.8 ± 0.35 15.2 ± 0.28 23.0 ± 0.19
6b 14.1 ± 0.08 20.1 ± 0.13 15.1 ± 0.23 11.2 ± 0.41 12.9 ± 0.06 15.2 ± 0.98 24.1 ± 0.65
6c 15.2 ± 0.16 18.1 ± 0.78 11.2 ± 0.63 11.9 ± 0.09 9.9 ± 0.62 13.8 ± 0.07 21.2 ± 0.33
6d 15.3 ± 0.68 18.2 ± 0.55 10.2 ± 0.37 – 13.2 ± 0.21 16.4 ± 0.78 24.2 ± 0.35
6e 12.1 ± 0.09 20.1 ± 0.43 10.1 ± 0.32 11.1 ± 0.19 12.1 ± 0.58 15.9 ± 0.55 25.3 ± 0.28
6f 15.2 ± 0.52 20.1 ± 0.26 12.2 ± 1.05 10.2 ± 0.36 12.1 ± 0.18 15.5 ± 0.48 25.1 ± 0.37
6g 13.1 ± 0.15 20.1 ± 0.72 – 10.1 ± 0.09 12.1 ± 0.28 15.9 ± 1.07 25.2 ± 0.39
6h 14.1 ± 0.09 20.3 ± 0.43 11.1 ± 0.30 10.2 ± 0.15 12.1 ± 0.86 13.8 ± 0.57 23.1 ± 0.22
6i 12.3 ± 0.08 21.1 ± 0.13 10.1 ± 0.23 12.2 ± 0.41 15.4 ± 0.06 16.4 ± 0.98 20.1 ± 0.65
6j 16.3 ± 0.34 21.2 ± 0.87 10.2 ± 0.51 13.1 ± 0.82 15.2 ± 0.74 15.2 ± 0.32 23.1 ± 0.47
5 14.9 ± 0.16 19.9 ± 0.12 11.9 ± 0.06 11.8 ± 0.19 13.8 ± 0.15 15.9 ± 0.17 19.9 ± 0.09
A 20.1 ± 0.57 21.2 ± 1.16 15.2 ± 0.67 – – – –
C 16.3 ± 0.28 30.4 ± 0.35 20.1 ± 0.16 – – – –
N – – – – 19.4 ± 0.51 19.5 ± 0.72 12.4 ± 0.42
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using a Buchi Melting Point B-540 apparatus and they are 
uncorrected. The FT-IR spectra were recorded on Hori-
zon MBTM FT-IR, over a 500–4000  cm−1 range, after 
16 scans at a resolution of 4 cm−1. The spectra process-
ing was carried out with the Horizon MBTM FTIR Soft-
ware. The 1H-NMR (400 MHz) and 13C-NMR (101 MHz) 
spectra were obtained on a Bruker Avance 400  MHz 
spectrometer using tetramethylsilane as internal stand-
ard and deuterated chloroform as solvent (CDCl3). The 
chemical shifts were shown in δ values (ppm). The mass 
spectra were registered using a Bruker MaXis Ultra-High 
Resolution Quadrupole Time-of-Flight Mass Spectrom-
eter. The progress of the reaction was monitored on 
TLC, using pre-coated Kieselgel 60 F254 plates (Merck, 
Whitehouse Station, NJ, USA) and the compounds were 
visualized using UV light. E-factor and material efficiency 
(ME) have been selected to evaluate the greenness of the 
synthetic procedures. E-factor is a very useful metric 
tool that is defined as E-Factor  =  mass of wastes/mass 
of product. The E-factor can be used to calculate the 
Table 7 Antibacterial effect expressed as MIC and MBC values (mg/mL) of 6a–j
5 = L-NO2-Arg-OMe, A = ampicillin; C = chloramphenicol; nt = no tested









MICa MBCa MICa MBCa MICa MBCa MICa MBCa
6a 2.5 2.5 0.01 0.01 1.25 1.25 2.5 2.5
6b 1.25 2.5 0.03 1.25 2.5 10 2,5 10
6c 0.01 0.01 0.01 0.03 0.03 0.03 5 5
6d 2.5 2.5 0.01 0.03 1.25 5 1.25 1.25
6e 0.01 0.3 0.01 0.01 10 5 5 5
6f 0.07 2.5 0.03 0.15 0.03 0.15 0.03 1.25
6g 2.5 2.5 0.03 1.25 1.25 1.25 2.5 10
6h 2.5 2.5 0.01 0.01 1.25 5 2.5 2.5
6i 0.3 0.3 0.01 0.01 0.1 0.1 0.03 0.6
6j 0.07 0.07 0.01 0.01 0.03 0.03 1.25 1.25
5 2.5 2.5 0.01 0.01 1.25 1.25 1.25 1.25
A 0.0002 0.0005 0.0002 0.0005 0.008 0.016 nt nt
C 0.008 0.016 0.003 0.006 0.008 0.016 nt nt
Table 8 Antifungal effect expressed as MIC and MFC values (mg/mL) of 6a–j
5 = -L-NO2-Arg-OMe, N = nystatin







MICa MFCa MICa MFCa MICa MFCa
6a 0.6 1.25 1.25 1.25 0.003 0.003
6b 0.6 1.25 2.5 10 0.003 0.003
6c 0.6 0.6 10 10 0.003 0.003
6d 0.3 1.25 0.6 2.5 0.003 0.003
6e 10 10 10 10 5 5
6f 0.6 0.6 2.5 5 0.003 0.003
6g 0.3 1.25 1.25 2.5 0.003 0.003
6h 0.3 5 10 10 0.003 0.003
6i 0.03 10 10 10 10 10
6j 0.3 1.25 1.25 1.25 0.003 0.003
5 1.25 1.25 0.6 2.5 0.003 0.003
N 0.004 0.008 0.004 0.008 0.004 0.008
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material efficiency of the process according to the equa-
tion: ME = 1/E-factor + 1 [40].
The antioxidant potential was investigated using in vitro 
methods based on ferric/phosphomolybdenum reducing 
antioxidant power and DPPH/ABTS radical scavenging 
assay. The antibacterial activity was evaluated using Gram-
positive (S. aureus ATCC 25923, S. lutea ATCC 9341) and 
Gram-negative (E. coli ATCC 25922 and P. aeruginosa 
ATCC 27853) bacterial strains. The antifungal activity 
was evaluated using C. albicans ATCC 10231, C. glabrata 
ATCC MYA 2950 and C. parapsilosis ATCC 22019. All 
strains were obtained from the Culture Collection of 
the Department of Microbiology, Gr. T. Popa University 
of Medicine and Pharmacy, Iasi, Romania. As positive 
controls were used ampicillin, a beta-lactam drug, and 
chloramphenicol which belongs amphenicoles class for 
antibacterial activity and nystatin for antifungal activity.
General procedure for synthesis 
of N2‑[(2‑aryl‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6a–j)
3-(2-Phenyl-4-oxo-1,3-thiazolidin-3-yl)propionic acid 
derivatives, 4a–j (5  mmol) were dissolved in 25  mL 
freshly distilled DCM, on ice bath at 0–5  °C and under 
inert atmosphere of nitrogen [41]. To the cold solu-
tion it was added EDCI.HCl (5.5  mmol, 1.1 equiv.), 
HOBt (5.5  mmol, 1.1 equiv.) and NO2-L-Arg-OMe.
HCl (5.5  mmol, 1.1 equiv.). The mixture was stirred for 
10–14  h at room temperature. The reaction monitoring 
was carried out by Thin Layer Chromatography (TLC) 
using as mobile phase DCM: methanol (MeOH)  =  9.5: 
0.5 (v/v) and the spot visualization was done under UV 
light at 254 nm. After the completion of the reaction, the 
mixture was washed successively with 1  M HCl, satu-
rated solution of sodium bicarbonate and saturated brine 
solution. The organic layer, was dried over anhydrous 
MgSO4, filtered and concentrated to dryness. Purification 
of compounds was carried out by column separation on 
silica gel (DCM/MeOH, 9.5/0.5). The appropriate frac-
tions of thiazolidine-4-one derivatives was collected and 
then evaporated to dryness to give the corresponding 
final derivatives.
N2‑[(2‑Phenyl‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6a)
White cristals, mp 102 °C, yield: 93 %, IR (Zn/Se crystal, 
cm−1): 3294 (–NH); 2963, 783 (=CHphenyl); 2869, 1250, 
725 (–CH2–); 1736 (COOCH3); 1647 (CONH); 1628 
(C=Othiazolidine-4-one); 1535 (–C=C–phenyl); 1350, 1026 
(–C–N–); 698 (C–S); 1H-NMR (δ ppm): 8.51 (s, 1H, NH–
CO), 8.03 (m, 1H, NH), 7.56–7.47 (m, 2H, NH), 7.38–
7.29 (m, 5H, Ar–H), 5.77 (d, J = 55.7 Hz, 1H, –N–CH–S), 
4.61 (s, 1H, CH2–S), 3.89 (s, 1H, CH2–S), 3.78 (s, 3H, CH3 
ester), 3.73 (s, 1H, CH–COOCH3), 3.69 (s, 1H, N–CH2), 
3.39–3.30 (m, 2H, CH2 arg), 3.23–3.01 (m, 1H, N–CH2), 
2.62–2.34 (m, 2H, CH2–CO), 1.94–1.54 (m, 4H, 2CH2 
arg); 13C-NMR (δ ppm): 172.32, 171.28, 162.09 (3C, CO), 
159.64 (Cguanid), 139.15, 129.72, 129.42, 127.45, 127.33, 
117.60 (6C, CAr), 64.36 (S–CH–N–), 52.99 (CH2), 48.47 
(CH), 39.75 (–CH2N–), 33.99 (–CH2S–), 33.33 (CH2), 
32.98 (–CH2CO), 24.29 (CH2), 20.57 (CH3); HRMS 
(EI-MS): m/z calculated for C19H26N6O6S [M  +  H]+ 
467.1707; found is 467.1705; Green chemistry metrics: 
E-factor 22.513, ME 0.042.
N2‑[(2‑(4‑Methylphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6b)
Light yellow cristals, mp 90  °C, yield: 91  %, IR (Zn/
Se crystal, cm−1): 3305 (–NH); 2951, 771 (=C–Hphe-
nyl); 2928, 1257, 721 (–CH2–); 1724 (COOCH3); 1678 
(CONH); 1628 (C=Othiazolidine-4-one); 1597 (–C=C–phe-
nyl); 1362, 1026 (–C–N–); 694 (C–S); 1H-NMR (δ ppm): 
8.68 (s, 1H, NH–CO), 8.31 (m, 1H, NH), 7.80 (s, 2H, 
NH), 7.26–7.34 (m, 4H, Ar–H), 5.82 (d, J  =  18.8  Hz, 
1H, –N–CH–S), 4.57 (s, 1H, CH2–S), 3.92 (dd, J = 13.6, 
6.8 Hz, 1H, CH2–S), 3.81 (s, 3H, CH3 ester), 3.78 (s, 1H, 
CH–COOCH3), 3.71 (s, 1H, N–CH2), 3.53–3.31 (m, 2H, 
CH2 arg), 3.24–3.05 (m, 1H, N–CH2), 2.62 (dd, J = 18.0, 
7.9 Hz, 2H, CH2–CO), 2.41 (s, 3H, CH3), 2.02–1.62 (m, 
4H, 2CH2 arg); 13C-NMR (δ ppm): 172.47, 171.28, 170.76 
(3C, CO), 159.40 (Cguanid), 138.24, 134.57 (2C, CAr), 
128.95 (2C, CHAr), 123.31 (2C, CHAr), 63.25 (S–CH–
N), 50.34 (CH), 40.73 (CH2), 39.58 (–CH2N–), 33.45 
(–CH2S–), 32.84 (–CH2CO), 29.14 (CH2), 24.29 (CH2), 
26.37, 21.34 (2C, CH3); HRMS (EI-MS): m/z calculated 
for C20H28N6O6S [M  +  H]+ 481.1862; found 481.1864; 
Green chemistry metrics: E-factor 16.891, ME 0.056.
N2‑[(2‑(4‑Chlorophenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6c)
Light yellow cristals, mp 146  °C, yield: 89  %; IR (Zn/Se 
crystal, cm−1): 3302 (–NH); 2951, 783 (=C–Hphenyl); 
2928, 1257, 725 (–CH2–); 1736 (COOCH3); 1651 (–
CONH); 1628 (C=Othiazolidine-4-one); 1597 (–C=C–phenyl); 
1342, 1014 (–C–N–);764 (C–Cl); 683 (C–S); 1H-NMR 
(δ ppm): 8.68 (s, 1H, NH–CO), 8.26 (m, 1H, NH), 7.75 
(s, 2H, NH), 7.32 (d, J =  8.2  Hz, 2H, Ar–H), 7.28–7.23 
(d, 2H, Ar–H), 5.75 (d, J  =  26.3  Hz, 1H, –N–CH-S), 
4.52 (s, 1H, CH2–S), 3.79 (dd, J = 15.8, 8.6 Hz, 1H, CH–
COOCH3), 3.71 (s, 1H, CH2–S), 3.68 (s, 3H, CH3 ester), 
3.64 (s, 1H, N–CH2), 3.31 (d, J = 44.9 Hz, 2H, CH2 arg), 
3.11–2.94 (m, 1H, N–CH2), 2.65–2.29 (m, 2H, CH2–
CO), 1.90–1.56 (m, 4H, 2CH2 arg); 13C-NMR (δ ppm): 
173.24, 171.99, 169.52 (3C, CO), 160.48 (Cguanid), 138.42, 
135.80 (CAr), 130.05 (2C, CHAr), 129.37 (2C, CHAr), 63.94 
(S–CH–N), 53.38 (CH2), 51.34 (CH), 41.42 (CH2), 39.10 
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(–CH2N–), 34.19 (–CH2S–), 31.53 (–CH2CO), 29.57 
(CH2); 26.45 (CH3); HRMS (EI-MS): m/z calculated for 
C19H25ClN6O6S [M  +  H]+ 501.1317; found 501.1310; 
Green chemistry metrics: E-factor 2.361, ME 0.297.
N2‑[(2‑(4‑Fluorophenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6d)
Light yellow cristals, mp 85  °C, yield: 75  %; IR (Zn/Se 
crystal, cm−1): 3302 (–NH); 2951, 787 (=C–Hphenyl); 
2933, 1257, 725 (–CH2–); 1736 (COOCH3); 1651 (–
CONH); 1647 (C=Othiazolidine-4-one); 1601 (–C=C–phenyl); 
1342, 1011 (–C–N–); 1153 (C–F); 687 (C–S); 1H-NMR 
(δ ppm): 8.63 (s, 1H, NH–CO), 8.24 (m, 1H, NH), 7.61 
(s, 2H, NH), 7.37 (dd, J = 13.7, 5.7 Hz, 2H, Ar–H), 7.11 
(t, J = 8.4 Hz, 2H, Ar–H), 5.80 (d, J = 50.0 Hz, 1H, –N–
CH–S), 4.72–4.41 (m, 1H, CH2–S), 3.94–3.85 (m, 1H, 
CH–COOCH3), 3.80 (s, 1H, CH2–S), 3.75 (s, 3H, CH3 
ester), 3.71 (s, 1H, N–CH2), 3.52–3.27 (m, 2H, CH2 arg), 
3.20–3.00 (m, 1H, N–CH2), 2.68–2.27 (m, 2H, CH2–CO), 
1.84–1.59 (m, 4H, 2CH2 arg); 13C-NMR (δ ppm): 171.80, 
170.76, 162.34 (3C, CO), 158.81 (Cguanid), 161.58, 135.57 
(2C, CAr), 128.32 (2C, CHAr), 115.61 (2C, CHAr), 62.65 
(S–CH–N), 52.15 (CH), 39.93 (–CH2N–), 38.85 (CH2), 
33.10 (–CH2S–), 32.16 (–CH2CO), 29.24 (CH2), 28.67 
(CH2), 21.34 (CH3); HRMS (EI-MS): m/z calculated for 
C19H25FN6O6S [M  +  H]+ 485.1614; found 485.1613; 
Green chemistry metrics: E-factor 1.122, ME 0.471.
N2‑[(2‑(4‑Bromophenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6e)
Light yellow cristals, mp 109  °C, yield: 87  %; IR (Zn/Se 
crystal, cm−1): 3294 (–NH); 2954, 776 (=C–Hphenyl); 
1736 (COOCH3); 1647 (–CONH); 1628 (C=Othiazolidine-
4-one); 1601 (–C=C–phenyl); 1342, 1007 (–C–N–); 1246, 
725 (–CH2–); 687 (C–S); 668 (C–Br); 1H-NMR (δ ppm): 
8.68 (s, 1H, NH–CO), 8.19 (m, 1H, NH), 7.76 (s, 2H, 
NH), 7.54 (d, J = 7.6 Hz, 2H, Ar–H), 7.36–7.16 (m, 2H, 
Ar–H), 5.79 (d, J = 29.5 Hz, 1H, –N–CH–S), 4.59 (s, 1H, 
CH2–S), 3.86 (dd, J  =  17.6, 10.2  Hz, 1H, CH2–S), 3.78 
(s, 3H, CH3 ester), 3.77 (s, 1H, CH–COOCH3), 3.72 (d, 
J = 15.6 Hz, 1H, N–CH2), 3.37 (d, J = 45.7 Hz, 2H, CH2 
arg), 3.09 (dd, J = 31.1, 10.2 Hz, 1H, N–CH2), 2.74–2.51 
(m, 1H, CH2–CO), 2.43–2,37 (m, 1H, CH2–CO), 1.82 (d, 
J =  78.0 Hz, 4H, 2CH2 arg); 13C-NMR (δ ppm): 172.47, 
170.18, 161.28 (3C, CO), 159.40 (Cguanid), 138.24, 132.34 
(2C, CAr), 128.95 (2C, CHAr), 123.31 (2C, CHAr), 63.25 
(S–CH–N), 52.71 (CH), 40.73 (CH2), 39.58 (–CH2N–), 
33.45 (–CH2S–), 32.04 (–CH2CO), 29.14 (CH2), 28,67 
(CH2), 25.44 (CH3); HRMS (EI-MS): m/z calculated for 
C19H25BrN6O6S [M  +  H]+ 545.0811; found 545.0812; 
Green chemistry metrics: E-factor 1.874, ME 0.352.
N2‑[(2‑(4‑Methoxyphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6f)
Light yellow cristals, mp 95  °C, yield: 86  %; IR (Zn/Se 
crystal, cm−1): 3298 (–NH); 3001, 783 (=C–Hphenyl); 1740 
(COOCH3); 1651 (–CONH); 1628 (C=Othiazolidine-4-one); 
1609 (–C=C–phenyl); 1346, 1111 (–C–N–); 1246, 725 (–
CH2–); 1153 (–OCH3); 687 (C–S); 1H-NMR (δ ppm): 
8.60 (s, 1H, NH–CO), 8.21 (m, 1H, NH), 7.63 (s, 2H, 
NH), 7.38–7.18 (m, 2H, Ar–H), 6.91 (d, J = 8.6 Hz, 2H, 
Ar–H), 5.73 (d, J = 42.3 Hz, 1H, –N–CH–S), 4.65–4.53 
(m, 1H, CH2–S), 3.90–3.84 (m, 1H, CH2–S), 3.82 (s, 3H, 
CH3 ester), 3.76 (d, J = 3.3 Hz, 3H, OCH3), 3.71 (s, 1H, 
CH–COOCH3), 3.52–3.27 (m, 2H, CH2 arg), 3.22–3.01 
(m, 1H, N–CH2), 2.61–2.48 (m, 1H, N–CH2), 2.42–2.27 
(m, 1H, CH2–CO), 1.95–1.85 (m, 1H, CH2–CO), 1.77–
1.54 (m, 4H, 2CH2 arg); 13C-NMR (δ ppm): 172.40, 
171.99, 160.63 (3C, CO), 159.62 (Cguanid), 130.67, 130.11 
(2C, CAr), 128.96 (2C, CHAr), 114.70 (2C, CHAr), 63.80 
(S–CH–N), 55.71 (CH), 52.92 (OCH3), 40.46 (CH2), 
39.56 (–CH2N–), 33.94 (–CH2S–), 32.92 (CH2), 29.51 
(–CH2CO), 23.68 (CH2), 21.45 (CH3); HRMS (EI-MS): 
m/z calculated for C20H28N6O7S [M  +  H]+ 497.1813; 
found 497.1813; Green chemistry metrics: E-factor 1.506, 
ME 0.403.
N2‑[(2‑(3‑Methoxyphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6g)
Light pink cristals, mp 103  °C, yield: 78  %; IR (Zn/
Se crystal, cm−1): 3298 (–NH); 3001, 771 (=C–H phe-
nyl); 2951, 1254, 725 (–CH2–); 1740 (COOCH3); 1651 
(-CONH); 1647 (C=Othiazolidine-4-one); 1601 (–C=C–phe-
nyl); 1338, 1041 (–C–N–); 1149 (–OCH3); 694 (C–S); 1H-
NMR (δ ppm): 8.52 (s, 1H, NH–CO), 8.09 (m, 1H, NH), 
7.52–7.47 (m, 2H, NH), 7.32 (t, J = 7.9 Hz, 1H, Ar–H), 
6.97–6.85 (m, 2H, Ar–H), 6.74 (dd, J  =  31.2, 7.7  Hz, 
1H, Ar–H), 5.72 (d, J  =  63.5, 5.7  Hz, 1H, –N–CH–S), 
4.68–4.54 (m, 1H, CH2–S), 3.94–3.85 (m, 1H, CH2–S), 
3.82 (s, 3H, CH3 ester), 3.79–3.78 (d, J  =  3.5  Hz, 3H, 
OCH3), 3.72 (s, 1H, CH–COOCH3), 3.57–3.29 (m, 2H, 
CH2 arg), 3.25–3.05 (m, 1H, N–CH2), 2.55 (dt, J = 7.6, 
6.9  Hz, 1H, N–CH2), 2.45–2.32 (m, 1H, CH2–CO), 
1.91 (dd, J  =  8.5, 4.0  Hz, 1H, CH2–CO), 1.77–1.55 
(m, 4H, 2CH2 arg); 13C-NMR (δ ppm): 172.37, 170.65, 
160.39 (3C, CO), 159.66 (Cguanid), 140.76, 130.52 (2C, 
CAr), 119.47, 114.98, 114.75, 113.11 (4C, CHAr), 64.07 
(S–CH–N), 55.56 (CH), 53.01 (OCH3), 40.57 (CH2), 
39.79 (–CH2N–), 34.05 (–CH2S–), 31.94 (–CH2CO), 
29.65, 24.27 (2CH2), 21.34 (CH3); HRMS (EI-MS): m/z 
calculated for C20H28N6O7S [M + H]+ 497.1813; found 
497.1812; Green chemistry metrics: E-factor 3.767, ME 
0.213.
Page 11 of 14Pânzariu et al. Chemistry Central Journal  (2016) 10:6 
N2‑[(2‑(2‑Methoxyphenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6h)
Light yellow cristals, mp 115  °C, yield: 76  %; IR (Zn/
Se crystal, cm−1): 3298 (–NH); 3078, 771 (=C–H phe-
nyl); 2947, 1242, 725 (–CH2–); 1736 (COOCH3); 1647 
(–CONH); 1628 (C=Othiazolidine-4-one); 1597 (–C=C–
phenyl); 1350, 1049 (–C–N–); 1153 (–OCH3); 683 (C–S); 
1H-NMR (δ ppm): 8.48 (s, 1H, NH–CO), 7.94 (m, 1H, 
NH), 7.50 (s, 2H, NH), 7.34 (t, J = 7.9 Hz, 1H, Ar–H), 
7.15 (dd, J = 13.1, 4.3 Hz, 1H, Ar–H), 7.05–6.92 (m, 1H, 
Ar–H), 6.84–6.74 (m, 1H, Ar–H), 6.08 (d, J = 37.2 Hz, 
1H, –N–CH–S), 4.69–4.51 (m, 1H, CH2–S), 3.94 (t, 
J =  7.2  Hz, 1H, CH2–S), 3.90–3.86 (s, 3H, CH3 ester), 
3.78 (d, J = 3.1 Hz, 3H, OCH3), 3.66–3.56 (m, 1H, CH–
COOCH3), 3.40 (dd, J  =  69.6, 5.1  Hz, 2H, CH2 arg), 
3.11 (ddd, J = 11.9, 9.6, 6.4 Hz, 1H, N–CH2), 2.72–2.53 
(m, 1H, N–CH2), 2.46 (dt, J =  15.2, 6.2  Hz, 1H, CH2–
CO), 2.01–1.86 (m, 1H, CH2–CO), 1.78–1.48 (m, 4H, 
2CH2 arg); 13C-NMR (δ ppm): 172.98, 171.33, 164.37 
(3C, CO), 159.94 (Cguanid), 157.47, 130.82 (2C, CAr), 
127.38 (CHAr), 121.55 (2C, CHAr), 111.78 (CHAr), 63.95 
(S–CH–N), 56.21 (CH), 53.30 (OCH3), 40.81 (CH2), 
39.19 (–CH2N–), 34.53 (–CH2S–), 33.10 (CH2), 31.43 
(–CH2CO), 24.91 (CH2), 22.17 (CH3); RMS (EI-MS): 
m/z calculated for C20H28N6O7S [M  +  H]+ 497.1813; 
found 497.1814; Green chemistry metrics: E-factor 
2.079, ME 0.325.
N2‑[(2‑(3‑Nitrophenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6i)
Light yellow cristals, mp 100  °C, yield: 50  %; IR (Zn/
Se crystal, cm−1): 3302 (–NH); 3090, 783 (=C–H phe-
nyl); 2951, 1257, 729 (–CH2–); 1736 (COOCH3); 1651 
(–CONH); 1632 (C=Othiazolidine-4-one); 1601 (–C=C–
phenyl); 1528, 1350 (NO2); 1219, 1095 (–C–N–); 683 
(C–S); 1H-NMR (δ ppm): 8.58 (s, 1H, NH–CO), 8.21 (d, 
J = 4.3 Hz, 2H, Ar–H), 8.03 (m, 1H, NH), 7.77–7.67 (m, 
1H, Ar–H), 7.61 (t, J =  8.0  Hz, 1H, Ar–H), 7.49–7.34 
(m, 2H, NH), 5.93 (d, J = 34.7 Hz, 1H, –N–CH–S), 4.60 
(s, 1H, CH2–S), 3.98–3.83 (m, 1H, CH2–S), 3.79 (s, 3H, 
CH3 ester), 3.76 (d, J  =  4.6  Hz, 1H, CH–COOCH3), 
3.59–3.39 (m, 2H, CH2 arg), 3.36–3.22 (m, 1H, N–
CH2), 3.24–3.00 (m, 1H, N–CH2), 2.74–2.35 (m, 2H, 
CH2–CO), 1.84–1.55 (m, 4H, 2CH2 arg); 13C-NMR (δ 
ppm): 173.24, 171.67, 168.34 (3C, CO), 160.14 (Cguanid), 
149.41, 142.55 (2C, CAr), 135.30, 133.92, 131.10, 129.30 
(4C, CHAr), 63.58 (S–CH–N), 53.54 (CH), 41.32 (CH2), 
39.41 (CH2N–), 34.37 (–CH2S–), 33.48 (CH2), 31.94 
(–CH2CO), 24.27 (CH2), 22.37 (CH3); HRMS (EI-MS): 
m/z calculated for C19H25N7O8S [M  +  H]+ 512.1558; 
found 512.1554; Green chemistry metrics: E-factor 
3.687, ME 0.2134.
N2‑[(2‑(2‑Nitrophenyl)‑4‑oxo‑1,3‑thiazolidin‑3‑yl)
propionyl]‑nitro‑l‑arginine methyl ester (6j)
Yellow cristals, mp 95  °C, yield: 98 %; IR (Zn/Se crystal, 
cm−1): 3302 (–NH); 2983, 767 (=C–Hphenyl); 2954, 1257, 
725 (–CH2–); 1736 (COOCH3); 1659 (–CONH); 1628 
(C=Othiazolidine-4-one); 1606 (–C=C–phenyl); 1524, 1342 
(NO2); 1215, 1115 (–C–N–); 687 (C–S); 1H-NMR (δ 
ppm): 8.58 (s, 1H, NH–CO), 8.21 (m, 1H, NH), 8.15–8.06 
(m, 1H, Ar–H), 7.72 (dd, J  =  11.5, 3.8  Hz, 1H, Ar–H), 
7.52 (dd, J = 11.4, 4.0 Hz, 1H, Ar–H), 7.35–7.28 (m, 1H, 
Ar–H), 7.20–7.14 (m, 2H, NH), 6.30 (d, J = 23.8 Hz, 1H, 
–N–CH–S), 4.57 (d, J =  7.2 Hz, 1H, CH2–S), 4.07–3.94 
(m, 1H, CH2–S), 3.77 (d, J  =  13.6  Hz, 3H, CH3 ester), 
3.71–3.66 (m, 1H, CH–COOCH3), 3.61 (dd, J  =  15.7, 
2.8 Hz, 2H, CH2 arg), 3.49–3.28 (m, 1H, N–CH2), 3.17–
3.02 (m, 1H, N–CH2), 2.71–2.47 (m, 1H, CH2–CO), 
2.02–1.85 (m, 1H, CH2–CO), 1.77–1.61 (m, 4H, 2CH2 
arg); 13C-NMR (δ ppm): 172.01, 170.56, 162.34 (3C, CO), 
159.04 (Cguanid), 146.93, 136.09 (2C, CAr), 134.38, 129.13, 
125.70, 116.24 (4C, CHAr), 63.95 (S–CH–N), 58.72 
(CH), 40.21 (CH2), 39.33 (–CH2N–), 33.64 (–CH2S–), 
31.27 (CH2), 31.94 (–CH2CO), 29.55 (CH2), 24.26 
(CH3); HRMS (EI-MS): m/z calculated for C19H25N7O8S 
[M  +  H]+ 512.1558; found 512.1559; Green chemistry 
metrics: E-factor 1.218, ME 0.452.
Biological evaluation
Antioxidant activity
DPPH radical scavenging assay
The radical scavenging activity of the tested compounds 
towards 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical 
was measured as described in literature [32] with minor 
modifications. The samples were dissolved in DMSO in 
order to form the stock solutions with the concentra-
tion of 20  mg/mL. From the stock solutions there were 
taken different volumes (50, 100, 150, 200 µL) and com-
pleted up to 200  µL with methanol, then it was added 
2800 µL of 0.1 mM DPPH methanol solution. The result-
ing mixture was kept in the dark for 60 min after which 
the absorbance was read at 517  nm against methanol, 
used as a blank solution. The final concentration of sam-
ple in the test tube was 0.33, 0.66, 0.99 and 1.32 mg/mL 
respectively. The DPPH radical-inhibiting capacity (radi-
cal scavenging ability) was calculated using the following 
formula:
where AC  =  absorbance of the DPPH solution, 
AS = absorbance of the sample. Vitamin E (α-tocopherol) 
was used as positive control and as references were used 






% = [(AC − AS)/AC]× 100
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in a similar manner with the samples. All determinations 
were performed in triplicate.
ABTS radical scavenging assay
The generation of radical cation ABTS·+ was carried 
out by treating the aqueous solution of 2,2′-azino-bis 
(3-ethylbenzothiazoline-6-sulfonic acid) (7  mM) with 
ammonium persulfate (2.45 mM). The resulting mixture 
was kept in the dark for 16 h to promote the formation 
of ABTS·+, as described in [33, 34]. The ABTS+ radical 
cation solution was diluted with ethanol to obtain an 
absorbance value of 0.7 ± 0.02 at 734 nm. Different sam-
ple volumes (10, 15, 25, 50 µL) from a stock solution of 
20  mg/mL in DMSO were mixed with DMSO to 50  µL 
and then 1950  µL of ABTS·+ solution were added. The 
final concentration of sample in the test tube was 0.1, 
0.15, 0.25 and 0.50 mg/mL respectively. After 6 min the 
absorbance was measured at 734 nm against a blank (eth-
anol) and the radical scavenging capacity was calculated 
according to the following equation:
where AC  =  absorbance of ABTS·+ alcoholic solu-
tion; AS  =  absorbance of the samples, read at 6  min 
after the addition of the ABTS·+ solution. Vitamin E 
(α-tocopherol) was used as positive control and as refer-
ences were used NO2-Arg-OMe and l-arginine, all three 
being processed in a similar manner with the samples. All 
determinations were performed in triplicate.
Phosphomolydenum reducing antioxidant power (PRAP) 
assay
The total antioxidant activity of tested compounds was 
evaluated using the phosphomolybdenum method 
according to the procedure described in the literature 
[35] with minor modifications. For each compound 
was prepared a stock solution with the concentration of 
20  mg/mL in DMSO, from which there were used dif-
ferent volumes (20, 40, 60, 80  µL) and completed with 
DMSO up to 200  µL. Over these samples it was added 
2 mL of the reagent solution (0.6 M sulfuric acid, 28 mM 
disodium hydrogen phosphate, and 4  mM ammonium 
molybdate). The samples were incubated at 95  °C for 
90 min at drying stove (oven). The final concentration of 
sample in the test tube was 0.18, 0.36, 0.54 and 0.72 mg/
mL respectively. After cooling to room temperature, the 
absorbance was read at 695 nm against a blank (200 mL 
DMSO +  2  mL reagent). Vitamin E (α-tocopherol) was 
used as positive control and as references were used 
NO2-Arg-OMe and l-arginine, all three being processed 
in a similar manner with the samples. All determinations 
were performed in triplicate.
(2)Scavenging activity % = [(AC−AS)/AC]× 100
Ferric reducing antioxidant power (FRAP) assay
The ferric reducing antioxidant power of the compounds 
was quantified by the method described by [36] with 
slight modifications. The compounds were tested at dif-
ferent concentrations (20, 10, 5, 2.5 mg/mL). To 0.5 mL 
of samples of each concentration it was added 0.5 mL of 
0.2  M phosphate buffer pH 6.6. The reaction was then 
initiated by the addition of 0.5 mL of potassium ferricy-
anide 1 % w/v, after which the samples are incubated at 
50 °C (oven) for 20 min and the completion of the reac-
tion takes place by addition of 0.5  mL trichloroacetic 
acid 10 % w/v. 1 mL from the resulting solution of each 
sample was diluted with 1 mL double distilled deionised 
water and finally 0.2 mL of ferric chloride 0.1 % w/v was 
added. The final concentration of sample in the test tube 
was 4.5454, 2.2727, 1.1360, 0.5681  mg/mL respectively. 
The mixture was left at room temperature for 10 min and 
then the absorbance was measured at 700  nm against a 
blank solution prepared similar to the sample, which 
contain 0.5 mL DMSO instead 0.5 mL sample. Vitamin E 
(α-tocopherol) was used as positive control and as refer-
ences were used NO2-Arg-OMe and l-arginine, all three 
being processed in a similar manner with the samples. All 
determinations were performed in triplicate.
Antibacterial/antifungal assays
Agar disc diffusion method Antibacterial and antifungal 
activity of the 6a–j derivatives expressed as diameter of 
inhibition area was evaluated by the standard disk dif-
fusion assay according to described protocols [42]. Prior 
to use, the strains (bacteria and yeasts) were diluted in 
sterile 0.9  % NaCl until the turbidity was equivalent to 
McFarland standard no. 0.5 (106 CFU/mL). The suspen-
sions were further diluted 1:10 in Mueller–Hinton agar 
for bacteria and Sabouraud agar for fungi and then spread 
on sterile Petri plates (25 mL/Petri plate). Sterile stainless 
steel cylinders (5 mm internal diameter; 10 mm height) 
were applied on the agar surface in Petri plates. In each 
cylinder 200 μL of sample solutions in DMSO (20 mg/mL) 
was added. As positive control there were used commer-
cial available discs containing ampicillin (25  mcg/disc), 
chloramphenicol (30  mcg/disc) and nystatin (100  mcg/
disc). DMSO was used as a negative control. The plates 
were incubated at 37 °C for 24 h (bacteria) and at 24 °C for 
48 h (fungi). The diameters of inhibition area developed 
after the incubation were measured.
The broth micro‑dilution method The minimum inhibi-
tory concentration (MIC) and the minimum bacteri-
cidal/fungicidal concentration (MBC/MFC) against 
bacteria and fungi respectively were determined by the 
two-fold dilution method, with minor modification [38]. 
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The active cultures of the bacteria and fungi were pre-
pared by transferring the loopful of cells from the stock 
culture to the conical flasks containing Mueller–Hinton 
broth for bacteria or Sabouraud broth for fungi. The cul-
tures were incubated at 37 °C for 24 h (bacteria) and at 
24 °C for 48 h (fungi) and then were diluted with fresh 
media to obtain an optical density value of 106  CFU/
mL. Different dilutions of the 6a–j derivatives made in 
the Mueller–Hinton broth (bacteria) and in Sabourand 
broth (fungi) were prepared in a 96-well microplate 
by the twofold dilution method in the concentration 
range of 10, 5, 2.5, 1.25, 0.625, 0.312, 0.156, 0.078, 0.039, 
0.0195, 0.009 and 0.0048  mg/mL. Then 10  µL of each 
strain (106  CFU/mL) was inoculated onto the micro-
plates. The plates were incubated again at 37 °C for 24 h. 
The lowest concentrations of the tested compounds 
which did not show any visual growth of the test strain, 
were determined as the MICs, which were expressed in 
mg/mL. For the determination of MBCs and MFCs, the 
MIC and the next higher concentrations of the sample 
were selected, spread on the agar plates, and incubated 
at 37 °C for 24 h. The concentration of the tested com-
pounds, which did not show any growth of the microor-
ganism on the agar plates, was determined as the MBC/
MFC and expressed in mg/mL. Each determination was 
performed in triplicate.
Conclusions
The present work is centered on the synthesis and biolog-
ical evaluation of new thiazolidine-4-ones derived from 
the methyl ester of nitro-l-arginine. The structure of the 
compounds was proven using spectral methods (IR, 1H-
NMR, 13C-NMR, MS). The antioxidant activity was quan-
tified using four in  vitro tests: DPPH/ABTS scavenging 
assays and ferric/phosphomolybdenum reducing antioxi-
dant power assays. The methoxy-substituted derivatives, 
6h (R = 2-OCH3) and 6g (3-OCH3), showed a high free 
radical scavenging ability, both for DPPH and ABTS radi-
cals. A good influence was exerted also by the nitro and 
bromo substitution. The 2-nitro-derivative, 6j, showed 
the best ABTS scavenging ability while the 4-bromo-
derivative, 6e, presented the best ferric and phosphomo-
lybdenum reducing antioxidant power. The compound 6j 
also showed a good antibacterial and antifungal activity. 
It was the most active on S. aureus, S. lutea and P. aer‑
uginosa and Candida spp. respectively. The encouraging 
preliminary results support the antioxidant and antibac-
terial/antifungal potential of the synthesized compounds 
and their possible applications in several diseases medi-
ated by reactive oxygen species (ROS) and susceptible to 
infections such as wound healing from burns.
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